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ABSTRACT (300/300 words) 
Objectives  
Bimatoprost–timolol (bimatoprost 0.03%–timolol 0.5% fixed-dose combination [FDC]) and 
tafluprost–timolol (tafluprost 0.0015%–timolol 0.5% FDC) eye drops are currently the only 
topical intraocular pressure (IOP)-reducing therapies available as preservative-free (PF) 
prostaglandin and timolol FDC. The aim of this study was to investigate changes to ocular 
signs and symptoms when patients with ocular hypertension (OH) or open-angle glaucoma 
(OAG) switched from PF or benzalkonium chloride (BAK)-preserved bimatoprost–timolol to 
PF tafluprost–timolol eye drops.  
Design  
This was a 12-week, open-label, phase IV study  
Setting 
Sixteen centres in Finland, German, Italy and the United Kingdom. 
Participants  
Patients with OH or OAG (IOP on medication ≤21 mmHg), treated with PF or BAK-preserved 
bimatoprost–timolol for ≥4 weeks before screening, and presenting with conjunctival 
hyperaemia and ≥1 ocular symptom.  
Interventions  
Patients were switched to PF tafluprost–timolol once daily in the treated eye(s).  
Primary and Secondary outcome measures  
The primary endpoints were change from screening to Week 12 in conjunctival hyperaemia 
and worst ocular symptom. The secondary outcome measures were changes from screening 
in ocular signs (other than conjunctival hyperaemia) and symptoms at Week 12. 
Results 
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Of 123 enrolled patients, 121 were included in the intention-to-treat dataset of which all were 
Caucasian and 54.5% were female; 76 patients used BAK-preserved bimatoprost–timolol 
and 45 used PF drops. Conjunctival hyperaemia and severity of worst ocular symptom 
following switch to PF tafluprost–timolol significantly reduced from screening to Week 12 in 
all patients (p<0.001). The percentage of patients with ocular signs and symptoms was 
significantly reduced at Week 12 compared with screening (p<0.001). IOP was not affected 
by the change of treatment. 
Conclusions  
Switching from BAK-preserved or PF bimatoprost–timolol to tafluprost–timolol reduced both 
signs and symptoms of ocular surface disease with no clinically relevant effect on IOP. 
Trial registration: EudraCT 2014-005273-37 
 
Strengths and limitations of this study 
 The study allows for comparison between the effects of PF tafluprost–timolol and 
both BAK-preserved and PF bimatoprost–timolol formulations 
 The study was conducted across 16 centres limiting bias  
 As this was not a randomised-controlled trial, there was a potential for selection bias; 
however, a randomised design would have been unethical as patients would have 
been required to adhere to medication that caused them notable ocular intolerance 
 An open-label design could not be avoided for this study because the packages of 
BAK-preserved and PF bimatoprost–timolol and PF tafluprost–timolol were not 
identical 
 Regression to the mean should be considered when interpreting the results 
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INTRODUCTION 
Glaucoma is a disorder often associated with elevated intraocular pressure (IOP) which, if 
left untreated, leads to retinal ganglion cell death, thinning of the retinal nerve fibre layer, 
optic nerve damage and cupping of the optic disc.[1] In 2013, approximately 64.3 million 
people were affected by glaucoma, and the number is expected to grow to 111.8 million by 
2040.[2]  
 
Medical treatment of ocular hypertension (OH) and open-angle glaucoma (OAG) focuses on 
the long-term control of IOP.[3, 4] Several categories of IOP-lowering topical drugs are 
available including prostaglandin analogues (PGA) (generally the first-line treatment), 
β-adrenergic blockers, carbonic anhydrase inhibitors, α-adrenergic agonists and miotics.[1] 
The greatest reduction of IOP is obtained with PGAs (25%–35%) followed by non-selective 
β-blockers (20%–25%), such as timolol; however, when patients fail to achieve IOP targets 
with monotherapy, fixed-dose combinations (FDCs) should be considered.[5] 
 
There are only two available PGA–timolol preservative-free (PF) FDCs; PF bimatoprost 
0.03%–timolol 0.5% (bimatoprost–timolol) and PF tafluprost 0.0015%–timolol 0.5% 
(tafluprost–timolol).[6] Despite numerous comparative efficacy studies to date, few have 
compared different PF PGA therapies.[7] While non-selective β-blockers, such as timolol, 
can cause bradycardia, arrhythmias, and reductions in blood pressure, PGAs lack systemic 
side effects[1] but may be associated with distinctive ocular adverse events (AEs), such as 
conjunctival hyperaemia.[6] Preservatives such as benzalkonium chloride (BAK) are toxic to 
the ocular surface and may aggravate the signs and symptoms of ocular surface disease 
(OSD).[8] In a recent study, conjunctival hyperaemia occurred at similar rates in 
BAK-preserved and PF bimatoprost–timolol-treated patients, suggesting that bimatoprost 
may have caused these AEs rather than the preservative.[9] Additionally, switching from 
BAK-preserved bimatoprost monotherapy to PF tafluprost monotherapy has been shown to 
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significantly reduce the severity of conjunctival hyperaemia. [10] The objective of the present 
study was to evaluate the changes in ocular signs and symptoms in patients diagnosed with 
OH or OAG who were treated with BAK-preserved (0.005%) or PF bimatoprost–timolol eye 
drops (bimatoprost 0.03%–timolol 0.5%; Allergan, Irvine, CA, USA) prior to the start of the 
study and switched to PF tafluprost–timolol eye drops (tafluprost 0.0015%–timolol 0.5%; 
Santen Pharmaceutical Co., Ltd, Osaka, Japan).   
 
MATERIALS AND METHODS 
Study design 
This was an open-label, phase IV clinical study (EudraCT registration number: 
2014-005273-37) conducted at 16 centres in Finland, Germany, Italy and the United 
Kingdom (UK) from June 2015 through to May 2016. The study was reviewed and approved 
by the appropriate Independent Ethics Committees in the participating countries and 
conducted in accordance with the Good Clinical Practice guidelines of the International 
Council on Harmonisation and the ethical principles of the Declaration of Helsinki. 
 
Patient population 
Patients included in this study were aged ≥18 years, diagnosed with OH or OAG, inclusive of 
both primary OAG and pseudoexfoliation glaucoma, and treated with bimatoprost–timolol in 
the evening (BAK-preserved or PF single-dose formulation) in one or both eyes for ≥4 weeks 
before screening. Patients presented at screening with conjunctival redness/hyperaemia of 
at least moderate severity (grade ≥2) in at least one treated eye and ≥one ocular symptom of 
at least mild severity (grade ≥2) in either eye. Exclusion criteria included: use of more than 
two active medicinal agents to treat OH or OAG in the 6 months prior to screening; anterior 
chamber angle grade <2 (Shaffer classification) in either treated eye; and any corneal 
abnormality or other condition preventing applanation tonometry, including prior refractive 
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eye surgery and IOP >21 mmHg in the treated eye(s) at screening. A full list of inclusion and 
exclusion criteria is presented in supplementary table S1. 
 
Treatments and assessments 
Eligible patients had used BAK-preserved or PF bimatoprost–timolol (bimatoprost 0.03%–
timolol 0.5%) eye drops in the evening for ≥4 weeks prior to screening. Study treatment kits, 
containing PF tafluprost–timolol eye drops (tafluprost 0.0015%–timolol 0.5%) in unit-dose 
containers, were dispensed to patients at the screening visit. Patients were not blinded to 
treatment because an open-label design could not be avoided owing to differences in 
packaging between BAK-preserved and PF bimatoprost–timolol and PF tafluprost–timolol. 
Each patient instilled one drop of tafluprost–timolol once daily at 21:00 (±1 hour) in the 
affected eye(s) for 12 weeks. Drug accountability documentation and dosing data from case 
report forms were used to assess treatment compliance. Patients were assessed at 
screening, and at 2, 6 and 12 weeks post screening. After Week 12, a post-study visit was 
scheduled, and the investigator was free to prescribe any IOP-lowering medication. 
 
Ocular signs and symptoms 
Ocular signs and symptoms were assessed at every visit and were defined by the criteria 
described in supplementary table S2. Ocular symptoms were evaluated per patient and 
treated eyes were considered together. Ocular signs were analysed in the worst eye 
designated for each sign at screening. The co-primary endpoints were changes from 
screening in conjunctival hyperaemia and worst ocular symptom at Week 12. The severity of 
conjunctival hyperaemia was assessed from screening through to Week 12. Use of the Ora 
CalibraTM Redness Scale #6.0 (0–4 scale) was made under licence from Ora, Inc. Patients 
indicated their perceived worst ocular symptom at screening. 
 
Secondary endpoints were changes from screening in ocular signs and symptoms, other 
than conjunctival hyperaemia, at Week 12. The patient was asked about each symptom by a 
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leading question, with symptoms graded 0 (none), 1 (trace), 2 (mild), 3 (moderate) or 4 
(severe). A total symptom score (0–20) was calculated. Fluorescein tear break-up time was 
assessed by examination of tear film under a slit lamp following instillation of 2 μL of non-
preserved 2% sodium fluorescein dye to the eyes. The time taken (in seconds) to form 
micelles or for dry spots to develop was recorded as the break-up time. Corneal and 
conjunctival fluorescein staining were also evaluated. Using reference pictures (Oxford 
Grading scale) the corneal fluorescein staining and nasal and temporal conjunctival 
fluorescein stainings were scored from 0 to V each. The presence of blepharitis was also 
evaluated, and the severity was graded 0 (none), 1 (mild), 2 (moderate) or 3 (severe). Tear 
production was assessed using the Schirmer-I test for 5 minutes without anaesthesia. 
 
AEs 
Treatment-emergent ocular and non-ocular AEs were reported at each post-screening visit. 
The information obtained included event term, report source, the seriousness of the event, 
onset and resolution date, frequency, severity, relation to study drop instillation, location 
(left/right eye, both or not applicable), study drug treatment action, and the investigator’s 
causality assessment of the study treatment and outcome. All AEs were coded using the 
latest Medical Dictionary for Regulatory Activities. 
 
Ocular safety and quality of life 
At each visit, IOP was measured in both eyes using Goldmann applanation tonometry; the 
right eye was measured first. Two consecutive measurements were taken to determine the 
mean IOP. If the initial two measurements differed by ≥3 mmHg, then a third measurement 
was taken and the median IOP was determined. Other measures of ocular safety and quality 
of life (QOL) are described in the supplementary information. 
 
Sample size  
A mean change of 0.37 units (SD 1.12) from screening in conjunctival redness/ 
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hyperaemia was assumed from the previous tafluprost switch studies [11].  Using these 
estimates, it was determined using a paired t-test that 100 patients would be required for a 
power of 90% for conjunctival hyperaemia and >99% for worst ocular symptom. [11,12]. The 
calculations were done using the nQuery Advisor (version 6.0). The paired t-test was initially 
used to calculate sample size. However, the Wilcoxon signed rank test was found to perform 
better for heavy-tailed distributions and was thus used for the primary analysis..  
 
Statistical methods 
The intention-to-treat (ITT) dataset included all enrolled patients who received at least one 
dose of tafluprost–timolol and had at least one post-screening primary outcome 
measurement available. The safety set included all enrolled patients who had at least one 
dose of study treatment and had a subsequent safety measurement. The primary outcome 
measures for ocular signs and symptoms were assessed using the Wilcoxon signed rank 
test. No imputations for missing data were carried out. However, sensitivity analyses using 
the last observation carried forward imputation were carried out for the primary outcome 
measures. The analyses of secondary outcome and IOP measures were completed using 
standard statistical methods for paired data (e.g. McNemar’s test for binary data, Wilcoxon 
signed rank test for ordinal data and the paired t-test for continuous data). For AEs, both 
patient and event counts were calculated, and events leading to discontinuations were 
summarised. Best corrected visual acuity, biomicroscopy, ophthalmoscopy, visual field test, 
drop discomfort and Comparison of Ophthalmic Medications for Tolerability (COMTol) are 
ocular safety and QOL outcomes, which were analysed descriptively. 
 
Patient involvement 
No patients were involved in setting the research question or the outcome measures, nor 
were they involved in the design or implementation of this study. There are no plans to 
involve patients in the dissemination of results as the open-label nature of the study meant 
that patients were aware of which medication they received. 
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RESULTS 
Patient demographics and baseline characteristics  
A total of 126 patients were screened. Of the 123 patients enrolled, two had no 
post-screening data and were excluded; therefore, 121 (98.4%) patients were included in the 
ITT analysis, of which 114 (94.2%) patients completed the study (BAK-preserved, n=71; PF, 
n=43) (figure 1). The safety set comprised of 123 patients. The mean (range) age was 66 
(36–86) years, and more than half of the patients were female (54.5%) (table 1). Of the 
patients, ~70% in both BAK-preserved and PF subgroups had used bimatoprost–timolol for 
at least 6 months; 76 patients had used BAK-preserved (62.8%) and 45 had used PF 
(37.2%) bimatoprost–timolol. Approximately 20% of patients were diagnosed with OH and 
75% with OAG. Most patients (91.7%) required treatment in both eyes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
 
 
 
Table 1 Demographics and baseline characteristics of enrolled patients 
Variable Bimatoprost–timolol Total 
(n=121) 
BAK-
preserved 
(n=76) 
PF  
(n=45) 
 
Mean age, years 
SD 
66.14 
10.17 
67.02 
10.71 
66.47 
10.34 
Sex, n (%) 
Male 34 (44.7) 21 (46.7) 55 (45.5) 
Female 42 (55.3) 24 (53.3) 66 (54.5) 
Race, n (%) 
Caucasian 76 (100) 45 (100) 121 (100) 
Hyperaemia, n (%) 76 (100) 45 (100) 121 (100) 
Hyperaemia grade, mean Ora 
calibra™ redness scale (SD) 
2.24 (0.43) 2.30 (0.48) 2.26 (0.45) 
Severity of worst ocular symptom, n (%) 
Mild 30 (39.5) 17 (37.8) 47 (38.8) 
Moderate 39 (51.3) 23 (51.1) 62 (51.2) 
Severe 7 (9.2) 5 (11.1) 12 (9.9) 
Abnormal ocular signs, n (%) 
Fluorescein tear break-up time 52 (68.4) 32 (71.1) 84 (69.4) 
Corneal fluorescein staining  63 (82.9) 42 (93.3) 105 (86.8) 
Conjunctival fluorescein staining  55 (72.4) 36 (80.0) 91 (75.2) 
Blepharitis  32 (42.1) 22 (48.9) 54 (44.6) 
Tear secretion/Schirmer test 47 (61.8) 29 (64.4) 76 (62.8) 
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Abnormal ocular symptoms, n (%) 
Irritation/burning/stinging 55 (72.4) 32 (71.1)  87 (71.9)  
Foreign body sensation 41 (53.9) 19 (42.2)  60 (49.6)  
Tearing 31 (40.8) 25 (55.6)  56 (46.3)  
Itching 36 (47.4) 26 (57.8)  62 (51.2)  
Dry eye sensation 49 (64.5) 28 (62.2)  77 (63.6)  
Please refer to supplementary table S2 for criteria of abnormal signs and symptoms.  
BAK, benzalkonium chloride; PF, preservative-free; SD, standard deviation. 
 
Changes to signs and symptoms 
A significant improvement was observed in the severity of both conjunctival hyperaemia and 
worst ocular symptom compared with screening after switching from bimatoprost–timolol to 
tafluprost–timolol (p<0.001 at Weeks 2, 6 and 12). The mean ± standard deviation grade of 
conjunctival hyperaemia for all patients decreased from 2.26±0.45 at screening to 0.94±0.64 
at Week 12 (a mean reduction of 58.5%) (figure 2A). The percentage of patients with 
conjunctival hyperaemia significantly reduced from 76 (100%) and 45 (100%) patients at 
screening in BAK-preserved and PF bimatoprost–timolol groups, respectively, to 47 (66.2%) 
and 31 (72.1%) at Week 12 (figure 2B). All patients identified a worst ocular symptom at 
screening, which was at least mild in severity; the number of patients with the identified 
symptom was reduced to 47 (41.2%) at Week 12. The number of patients with moderate and 
severe worst ocular symptom decreased from 62 (51.2%) and 12 (9.9%) at screening, to 11 
(9.6%) and one (0.9%) at Week 12, respectively (figure 2C). In the BAK-preserved and PF 
bimatoprost–timolol subgroups, the number of patients with moderate and severe worst 
ocular symptom decreased from 46 (60.5%) to five (7.0%) patients and from 28 (62.2%) to 
seven (16.3%) patients, respectively (figure 2D). 
 
The frequencies of abnormal ocular signs and symptoms were significantly reduced at Week 
12 after switching from bimatoprost–timolol to tafluprost–timolol (p<0.012 for signs and 
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p<0.001 for symptoms) (figures 3A, B, C and D). For ocular signs, the greatest relative 
reductions from screening were observed in tear secretion (screening, 62.8%; Week 12, 
37.7%) and blepharitis (screening, 44.6%; Week 12, 27.2%). For ocular symptoms, all 
relative reductions were over 50%, and the greatest were observed in foreign body 
sensation (screening, 49.6%; Week 12, 20.2%) and itching (screening 51.2%; Week 12, 
21.9%). 
 
AEs 
Overall, 70 treatment-emergent AEs based on the safety dataset (n=123) were reported by 
41 (33.3%) patients during the study, of which 15 events in 12 (9.8%) patients were ocular 
and 55 events in 34 (27.6%) patients were non-ocular (table 2). Only 12 AEs in ten (8.1%) 
patients were classified as being related to tafluprost–timolol. Two patients had serious AEs: 
worsening of arterial branch occlusion (resolved after 4 weeks) and paroxysmal atrial flutter 
with high-grade atrioventricular block (resolved in 2 days); both of which were adjudicated by 
the investigator and sponsor to be unrelated to tafluprost–timolol treatment. A total of five 
patients discontinued the study because of AEs, which were: two cases of moderate 
increase in IOP; moderate pruritus and eye pruritus, a moderate urticaria; and a severe 
increase in lacrimation. There were no deaths during the study. 
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Table 2 The occurrence of related and unrelated ocular and non-ocular AEs in patients 
(n=123) after switching from bimatoprost–timolol to tafluprost–timolol 
MedDRA preferred term Mild/moderate Severe 
Related ocular AEs 
Lacrimation increased 0 1 
IOP increased   3 0 
Eye pruritus  1 0 
Pruritus  1 0 
Eyelid irritation 1 0 
Related non-ocular AEs 
Urticaria  1 0 
Abdominal pain upper  1 0 
Dysgeusia  1 0 
Headache  1 0 
Somnolence 1 0 
Unrelated ocular AEs in ≥2 patients 
Ocular hyperaemia 1 1 
Unrelated non-ocular AEs in ≥2 patients 
Headache 10 0 
Nasopharyngitis 4 0 
Pyrexia 3 0 
Rhinitis    3 0 
Cough 3 0 
Arthralgia 2 0 
Back pain    2 0 
AE, adverse event; IOP, intraocular pressure; MedDRA, Medical Dictionary for Regulatory Activities. 
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Ocular safety and QOL 
At screening, IOP was well controlled with bimatoprost–timolol treatment (n=123; mean IOP 
15.9±2.1 mmHg); this was sustained at Week 12 (n=114; mean IOP 16.3±2.3 mmHg) and 
was clinically insignificant and statistically non-inferior compared with screening 
(0.34 mmHg; 95% upper limit 0.86 mmHg; P=0.134). IOP was maintained at ≤21 mmHg for 
>97% of patients and ≤18 mmHg for >80% of patients. Other results for ocular safety and 
QOL are described in the supplementary information (table S3). 
 
DISCUSSION 
Medical treatment of glaucoma aims to maintain patients’ visual function and QOL; however, 
nearly all patients with glaucoma will require a combined therapy to attain a greater than 
30% 24-hour IOP reduction.[13, 14] Currently there are only two PF prostaglandin–timolol 
formulations available: PF bimatoprost–timolol and tafluprost–timolol. In this study, the 
effects of switching from bimatoprost–timolol to tafluprost–timolol on signs and symptoms of 
OSD and the effect of these changes in QOL were evaluated. 
 
The study met both co-primary endpoints showing significant improvements in conjunctival 
hyperaemia and worst ocular symptom from screening to Week 12. No statistical evidence of 
heterogeneity in the occurrence of ocular signs and symptoms was found between prior 
BAK-preserved and PF bimatoprost–timolol. This study has shown that patients receiving 
bimatoprost–timolol who present with signs and symptoms of OSD benefit from switching to 
tafluprost–timolol. Control of IOP was maintained, and there were no reports of unexpected 
AEs related to tafluprost–timolol or significant findings in ocular safety during the study. In 
this study, both the preserved and PF groups experienced a reduction in overall signs and 
symptoms. These results agree with a previous study, which found that the severity of both 
conjunctival hyperaemia and punctuate keratitis was significantly higher with bimatoprost 
than tafluprost (p<0.02 and p<0.04 respectively) [10]. Additionally, these results agree with a 
previous double-blind phase III study where no significant differences in safety and 
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tolerability between BAK-preserved and PF bimatoprost–timolol were observed except for 
more frequent skin pigmentation with PF bimatoprost–timolol.[9] The observed ocular 
surface abnormalities and improved tolerability may thus be related to the prostamide-
mimetic properties of bimatoprost as opposed to the preservative component of the 
bimatoprost–timolol formulation. However, there are studies that suggest that BAK may have 
a significant role in causing tolerability issues with PGA monotherapy despite once-daily 
dosing. A recent meta-analysis of two Phase 3 studies including 339 patients who had 
switched from BAK-preserved latanoprost to PF tafluprost resulted in significant reductions 
in ocular signs and symptoms.[11] Timolol treatment has been shown to induce only minimal 
hyperaemia or irritation in the eye.[6] In this study, the percentage of symptom-free patients 
increased by Week 12 concomitantly with improved ocular tolerability as reported in the 
COMTol questionnaire after switching from bimatoprost–timolol to tafluprost–timolol. This 
agrees with a previous study that found an association between advanced OSD and poorer 
glaucoma-related QOL than in patients without OSD.[15] The aforementioned study also 
reported that OSD was associated with higher daily doses of BAK.  
 
This study had several limitations. This was not a randomised controlled trial, and there was 
a potential for selection bias; however, a parallel-group (randomised) design with 
bimatoprost–timolol was considered unethical, because the patients would have continued 
using medication that caused them notable ocular intolerance. An open-label design could 
not be avoided for this study because the packages of BAK-preserved and PF bimatoprost–
timolol and PF tafluprost–timolol were not identical. IOP readings were unmasked and may 
also have been subject to bias. ‘Regression toward the mean’ is the observation that if a 
variable is extreme on the first measurement, it will tend to be closer to the average on its 
second measurement. This may have introduced reduction in some ocular signs and should 
also be considered in the interpretation of these results. Compliance is likely to be higher in 
a study setting, and so these results may not be reflective of a real-world setting. Treatment 
persistence could not be investigated thoroughly because PF tafluprost–timolol was only 
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commercially available for 26 patients in two of the participating countries (UK and Finland) 
at the time of the study. 
In conclusion, switching from bimatoprost–timolol to tafluprost–timolol yielded clinical 
benefits in the presence of signs and symptoms of OSD in patients with OH and OAG over 
12 weeks. Tafluprost–timolol provides a potential alternative treatment option for patients 
with OH or OAG.  
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Figure 1 Patient disposition by previous bimatoprost–timolol treatment. After initial 
screening, three patients did not meet the inclusion criteria. A total of nine (7.4%) patients 
discontinued the study; five discontinued because of AEs and four withdrew from the study. 
BAK, benzalkonium chloride; PF, preservative-free. 
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Figure 2 Comparison of Week 12 outcomes with screening in conjunctival hyperaemia 
and worst ocular symptom after switching from bimatoprost–timolol to tafluprost–timolol (A) 
change in conjunctival hyperaemia from screening (n=121) to Week 12 (n=114); (B) 
breakdown of changes in conjunctival hyperaemia severity by subgroup at Week 12 
compared with screening. One patient in the ITT dataset violated inclusion criterion 2 and 
only had mild conjunctival hyperaemia at screening; (C) severity of worst ocular symptom at 
screening and Week 12 in all patients; and (D) changes in severity of worst ocular symptom 
by subgroup at Week 12 compared with screening. BAK, benzalkonium chloride; ITT, 
intention-to-treat; PF, preservative-free. 
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Figure 3 Secondary endpoints (A) abnormal ocular signs at screening (n=121); (B) 
abnormal ocular signs at Week 12 (n=114); (C) abnormal ocular symptoms at screening; (D) 
abnormal ocular symptoms at Week 12. BAK, benzalkonium chloride; PF, preservative-free. 
 
  
